Guardant Health (NASDAQ:GH) and Galenica (OTCMKTS:GALNF) Head to Head Survey

Galenica (OTCMKTS:GALNF) and Guardant Health (NASDAQ:GH) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Valuation & Earnings

This table compares Galenica and Guardant Health”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galenica	N/A	N/A	N/A	N/A	N/A
Guardant Health	$982.02 million	23.33	-$416.28 million	($3.49)	-48.92

Galenica has higher earnings, but lower revenue than Guardant Health.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Galenica and Guardant Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galenica	0	1	0	0	2.00
Guardant Health	1	0	23	1	2.96

Guardant Health has a consensus price target of $183.78, suggesting a potential upside of 7.65%. Given Guardant Health’s stronger consensus rating and higher possible upside, analysts plainly believe Guardant Health is more favorable than Galenica.

Profitability

This table compares Galenica and Guardant Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Galenica	N/A	N/A	N/A
Guardant Health	-38.33%	N/A	-25.40%

Institutional & Insider Ownership

92.6% of Guardant Health shares are owned by institutional investors. 5.6% of Guardant Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Guardant Health beats Galenica on 7 of the 9 factors compared between the two stocks.

About Galenica

Galenica AG operates as a healthcare service provider in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands. This segment also offers medication for treatment of patients at home; launches and distributes a portfolio of consumer health, pharmaceutical, and parapharmaceutical products; and marketing and sale services to partners in the healthcare market. The Logistics & IT segment provides range of specialized pre-wholesale services, including storage, distribution, and debt collection to pharmaceutical and healthcare companies. This segment also offers master data system for the healthcare market; develops management solutions for the healthcare market; group internal IT services; and publishes printed and electronic technical information on pharmaceutical products, as well as complete management solutions for pharmacies. The company was founded in 1927 and is headquartered in Bern, Switzerland.

About Guardant Health

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.